JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

ALLERGOLOGIA ET IMMUNOPATHOLOGIA is a distinguished academic journal dedicated to the field of immunology and allergy, published by CODON PUBLICATIONS, based in Singapore. With its ISSN 0301-0546 and E-ISSN 1578-1267, this journal aims to provide an open platform for researchers and practitioners to share their findings, emphasizing topics related to immunopathology and respiratory health. Covering a broad scope from 1973 to 2024, it currently holds a notable position in several category quartiles, including Q3 in Immunology and Allergy, and Q3 in Pulmonary and Respiratory Medicine as of 2023. Despite the absence of an open access option, the journal maintains an essential role in disseminating pivotal research, reflected in its Scopus rankings that position it within the core of its discipline. With an impact factor acknowledging the significance of its contributions, ALLERGOLOGIA ET IMMUNOPATHOLOGIA continues to be a vital resource for ongoing education and advancement in immunological and allergic research.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

Chinese Medicine is a distinguished open-access journal published by BMC, focusing on the advancement of knowledge and practice in the domain of complementary and alternative medicine. With the ISSN 1749-8546, this journal has established itself as an important resource for researchers, professionals, and students interested in the integration of traditional Chinese medicine with modern scientific practices. Since its inception in 2006, it has garnered a notable reputation, achieving a Q1 ranking in Complementary and Alternative Medicine and Q2 in Pharmacology for 2023, reflecting its high impact and relevance within the academic community. The journal's commitment to disseminating quality research is evident in its Scopus rankings, placing it in the top decile for medicine and pharmacology disciplines. Open access since its launch, Chinese Medicine promotes widespread accessibility and encourages collaborative scholarly efforts in investigating the efficacy and applications of traditional practices in contemporary healthcare. By fostering a platform for rigorous discourse and innovative research, this journal serves as an essential conduit for advancing the understanding of Chinese medicine's role in global health.

Natural Products Journal, a leading publication by Bentham Science Publishers, primarily focuses on the rapidly evolving field of Natural Products and their applications in Complementary and Alternative Medicine as well as Drug Discovery. With an ISSN of 2210-3155 and an E-ISSN of 2210-3163, this journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the critical role of natural compounds in health and medicine. Since its inception in 2011, it has consolidated its reputation, achieving a Q3 ranking in Complementary and Alternative Medicine and a Q4 ranking in Drug Discovery as of 2023, illustrating its growing influence within the academic community. Although it currently does not operate as an Open Access journal, it remains a vital resource for cutting-edge research and developments in natural products, offering insightful contributions that pave the way for innovative therapeutic strategies. Located in the Netherlands, the journal is pivotal for those looking to stay at the forefront of research in natural substances and their multifaceted applications.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Jundishapur Journal of Natural Pharmaceutical Products, published by BRIEFLAND in the Netherlands, serves as a pivotal platform for researchers and professionals in the realm of pharmacology and toxicology. With its ISSN 1735-7780 and E-ISSN 2228-7876, the journal has established itself since its inception in 2011, showcasing a commitment to advancing knowledge in natural pharmaceutical products through innovative research. In 2023, it earned a commendable ranking in the Q3 category for Pharmacology, Toxicology, and Pharmaceutics, reflecting its contribution to the field as evidenced by its position in the Scopus rankings. The journal aims to publish high-quality research articles, reviews, and case studies that explore the potential benefits and toxicological aspects of natural products. Although it currently does not offer open access, its rigorous peer-review process ensures that only impactful studies are disseminated, ultimately facilitating a deeper understanding of natural pharmaceutical innovations. For those engaged in this exciting and evolving field, Jundishapur Journal of Natural Pharmaceutical Products is an essential resource that not only expands scholarly discourse but also promotes safe practices in natural product utilization.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.